Department of Clinical Neurosciences, Institute of Neurology, University College London, Rowland Hill Street, London, NW3 2PF, UK.
Neurodegener Dis. 2010;7(1-3):210-2. doi: 10.1159/000295666. Epub 2010 Mar 12.
The development of a drug or combination of drugs to slow or stop the progression of Parkinson's disease is the most important goal in this disease area. An understanding of the complex etiology and pathogenesis of the disorder is essential in this process. However, the current pathways to disease pathogenesis identified from the genetic causes of Parkinson's disease offer optimism in the sense that they appear to converge and interconnect rather than diverge. Problems include the limited applicability of current models and the ability to test drugs at the right dose in clinical trials with suitable end points. Trials conducted so far have provided some indication of a positive effect, although the mechanism underlying this is not yet known.
开发一种能够减缓或阻止帕金森病进展的药物或药物组合是该疾病领域的最重要目标。在这个过程中，深入了解疾病复杂的病因和发病机制是必不可少的。然而，从帕金森病的遗传原因中确定的目前疾病发病机制的途径提供了乐观的前景，因为它们似乎汇聚和相互关联，而不是发散。存在的问题包括当前模型的适用性有限，以及在具有合适终点的临床试验中以适当剂量测试药物的能力。迄今为止进行的试验提供了一些积极效果的迹象，尽管其背后的机制尚不清楚。
